Skip to main content
SpringerLink
Log in

Preliminary biological evaluation of rhenium-188-MAG3-PSMA

  • Published:
Journal of Radioanalytical and Nuclear Chemistry Aims and scope Submit manuscript

Abstract

Prostate-specific membrane antigen (PSMA) is a biomarker for prostate cancer, which is commonly used in the development of diagnostic and therapeutic drugs for prostate cancer. In this study, rhenium-188 was chelated with mercaptoacetyltriglycine (MAG3)-PSMA to obtain 188Re-MAG3-PSMA. The labeling efficiency was greater than 99% under the optimal labeling conditions, and it was stable in saline and 10% FBS (fetal bovine serum) after 72 h of incubation. In cellular assays, uptake in PSMA (+) 22Rv1 cells was four-fold greater than that in PSMA (-) PC-3 cells. Biodistribution results revealed that the tumor-to-muscle ratio reached a maximum at 4 h after injection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Siegel RL et al (2021) Cancer statistics, 2021. CA 71(1):7–33

    PubMed  Google Scholar 

  2. Li X, Zeng X (2021) Advances in epidemiology of prostate cancer in China. Cancer Res Prev Treat 48(1):98–102

    Google Scholar 

  3. Denmeade SR, Isaacs JT (2002) A history of prostate cancer treatment. Nat Rev Cancer 2(5):389–396

    Article  CAS  Google Scholar 

  4. Park JC, Eisenberger MA (2015) Advances in the treatment of metastatic prostate cancer. Mayo Clin Proc 90(12):1719–1733

    Article  CAS  Google Scholar 

  5. Heidenreich A et al (2013) Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know. Eur Urol 64(2):260–265

    Article  Google Scholar 

  6. Barrio M et al (2016) Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer. Expert Rev Mol Diagn 16(11):1177–1188

    Article  CAS  Google Scholar 

  7. Afshar-Oromieh A, Zechmann CM, Malcher A et al (2014) Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41:11–20

    Article  CAS  Google Scholar 

  8. Jia Z-Y et al (2008) Rhenium-188 labelled meso-tetrakis 3,4-bis (carboxymethyleneoxy) phenyl porphyrin for targeted radiotherapy: preliminary biological evaluation in mice. Eur J Nucl Med Mol Imaging 35(4):734–742

    Article  CAS  Google Scholar 

  9. Juweid M et al (1998) Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer. J Nucl Med 39(1):34–42

    CAS  PubMed  Google Scholar 

  10. Miao Y, Owen NK, Fisher DR, Hoffman TJ, Quinn TP (2005) Therapeutic efficacy of a 188Re-labeled alpha-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J Nucl Med 46(1):121–129

    CAS  PubMed  Google Scholar 

  11. Nassar MY et al (2011) Synthesis of a Re-188-DTPMP complex using carrier-free Re-188 and study of its stability. J Radioanal Nucl Chem 287(3):779–785

    Article  CAS  Google Scholar 

  12. Wang Y et al (2020) Radionuclide Re-188-loaded photothermal hydrogel for cancer theranostics. Part Part Syst Charact. https://doi.org/10.1002/ppsc.201900421

    Article  Google Scholar 

  13. Hashimoto K (1998) Synthesis of a Re-188-HEDP complex using carrier-free Re-188 and study of its stability. Appl Radiat Isot 49(4):351–356

    Article  CAS  Google Scholar 

  14. Lee C-H et al (2021) The feasibility of Cu-64-PSMA I&T PET for prostate cancer. Cancer Biother Radiopharma. https://doi.org/10.1089/cbr.2020.4189

    Article  Google Scholar 

  15. Huang Y et al (2021) Synthesis and preclinical evaluation of an (AlF)-F-18 radiofluorinated bivalent PSMA ligand. Eur J Med Chem. https://doi.org/10.1016/j.ejmech.2021.113502

    Article  PubMed  PubMed Central  Google Scholar 

  16. Benesova M et al (2015) Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med 56(6):914–920

    Article  CAS  Google Scholar 

  17. Gorges TM et al (2016) Heterogeneous PSMA expression on circulating tumor cells—a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer. Oncotarget 7(23):34930–34941

    Article  Google Scholar 

Download references

Acknowledgements

This study was funded by the National Natural Science Foundation of China (Grant No. 11705268).

Author information

Authors and Affiliations

  1. Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China

    Hong Wang, Le Cai, Shu-Hua He, Xiao-Bei Zheng, Yu-Xia Liu & Lan Zhang

  2. University of Chinese Academy of Sciences, Beijing, 100049, China

    Hong Wang, Le Cai, Shu-Hua He & Xiao-Bei Zheng

Authors
  1. Hong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Le Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shu-Hua He
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiao-Bei Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu-Xia Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yu-Xia Liu or Lan Zhang.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, H., Cai, L., He, SH. et al. Preliminary biological evaluation of rhenium-188-MAG3-PSMA. J Radioanal Nucl Chem 331, 2553–2559 (2022). https://doi.org/10.1007/s10967-022-08306-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10967-022-08306-0

Keywords

Search

Navigation